SCHEMBL26083585

SCHEMBL26083585

COc1ccc(C(=O)COc2ccc(N3C(=O)C=CC3=O)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGLL Q99685 1/20 0.64
▸ MAPT P10636 4/20 0.56
▸ ALDH1A1 P00352 3/20 0.56
▸ HTT P42858 2/20 0.56
▸ HSD17B10 Q99714 1/20 0.56
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ POLB P06746 2/20 0.50
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ KDM4E B2RXH2 1/20 0.50
▸ HSP90AA1 P07900 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ CACNA1B Q00975 1/20 0.50
▸ APBA1 Q02410 1/20 0.50
▸ NPSR1 Q6W5P4 1/20 0.50
▸ TDP1 Q9NUW8 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ MET P08581 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21100591 0.83 MAPT (0.73) MAPTALDH1A1HTTHSD17B10NPC1
SCHEMBL136617 0.80 MGLL (1.00) MGLLALDH1A1HTTMEN1KMT2A
SCHEMBL10883921 0.79 MGLL (0.77) MGLLMAPTALDH1A1HTTMEN1
SCHEMBL27122580 0.78 MGLL (0.70) MGLLMAPTALDH1A1HTTMEN1
SCHEMBL28071934 0.78 MGLL (0.96) MGLLALDH1A1HTTMEN1KMT2A
SCHEMBL26083593 0.78 NPC1 (0.70) MAPTALDH1A1HTTMEN1KMT2A
SCHEMBL26109411 0.78 NPC1 (0.61) MAPTALDH1A1HTTHSD17B10KMT2A
SCHEMBL26111371 0.78 NPC1 (0.70) MAPTALDH1A1HTTMEN1KMT2A
SCHEMBL26083588 0.78 NPC1 (0.61) MAPTALDH1A1HTTHSD17B10KMT2A
SCHEMBL7168347 0.77 MAPT (0.71) MAPTALDH1A1HTTHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034091-A1 Small molecule inhibitors of lanosterol synthase BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-01-30 — — US disclosed
CN-119136798-A Small molecule lanosterol synthase inhibitors 德克萨斯州立大学董事会 2024-12-13 — — CN disclosed
WO-2023192782-A2 SMALL MOLECULE INHIBITORS OF LANOSTEROL SYNTHASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-10-05 — — WO disclosed
WO-2023192782-A2 SMALL MOLECULE INHIBITORS OF LANOSTEROL SYNTHASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034091-A1 Small molecule inhibitors of lanosterol synthase LSS, CYP51A1, CYP27A1 MGLL 1765/4885MAPT 182/4885ALDH1A1 3791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback